# Nirsevimab

## BEYFORTUS inj 100mg/1mL

| TAH Drug Code      | [IBEY100](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBEY100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Respiratory syncytial virus, prophylaxis: Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season and pediatric patients up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | Administer shortly before the RSV season begins; if not administered before start of season, may administer at any time during the season. Patient's first RSV season: Infants: Weight <5 kg: IM: 50 mg as a single dose. Weight >=5 kg: IM: 100 mg as a single dose. Patients who undergo cardiopulmonary bypass after dose: Administer an additional dose as follows as soon as patient is stable after surgery: <=90 days since initial dose: IM: 100 mg as a single dose. >90 days since initial dose: IM: 50 mg as a single dose. Patient's second RSV season: Infants and Children <24 months: IM: 200 mg as a single dose. Patients who undergo cardiopulmonary bypass after dose: Administer an additional dose as follows as soon as patient is stable after surgery: <=90 days since initial dose: IM: 200 mg as a single dose. >90 days since initial dose: IM: 100 mg as a single dose. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | Serious hypersensitivity (eg, anaphylaxis) to nirsevimab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | <1%: Dermatologic: Skin rash (0.9%) Local: Injection-site reaction (0.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/nirsevimab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

